Priorities in Parkinson's disease research. - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Nature Reviews Drug Discovery Année : 2011

Priorities in Parkinson's disease research.

Résumé

The loss of dopaminergic neurons in the substantia nigra pars compacta leads to the characteristic motor symptoms of Parkinson's disease: bradykinesia, rigidity and resting tremors. Although these symptoms can be improved using currently available dopamine replacement strategies, there is still a need to improve current strategies of treating these symptoms, together with a need to alleviate non-motor symptoms of the disease. Moreover, treatments that provide neuroprotection and/or disease-modifying effects remain an urgent unmet clinical need. This Review describes the most promising biological targets and therapeutic agents that are currently being assessed to address these treatment goals. Progress will rely on understanding genetic mutations or susceptibility factors that lead to Parkinson's disease, better translation between preclinical animal models and clinical research, and improving the design of future clinical trials.
Fichier non déposé

Dates et versions

hal-01222559 , version 1 (30-10-2015)

Identifiants

  • HAL Id : hal-01222559 , version 1
  • PUBMED : 21532567

Citer

Wassilios G Meissner, Mark Frasier, Thomas Gasser, Christopher G Goetz, Andres Lozano, et al.. Priorities in Parkinson's disease research.. Nature Reviews Drug Discovery, 2011, 10 (5), pp.377-93. ⟨hal-01222559⟩
59 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More